A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis

Article Dermatology

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics

John E. Jett et al.

Summary: The study demonstrated that tapinarof cream 1% once daily showed good tolerability and significant efficacy in patients with extensive plaque psoriasis, with 14 patients showing a >= 1-grade improvement in PGA score after 29 days.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

A novel topical treatment for plaque psoriasis: Benvitimod/tapinarof

Jianzhong Zhang et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Tapinarof Cream 1%: First Approval

Susan J. Keam

Summary: Tapinarof cream 1% is a novel topical treatment for plaque psoriasis that has been approved in the USA and is also being investigated for atopic dermatitis.

DRUGS (2022)

添加到收藏夹

Article Dermatology

One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial

Bruce Strober et al.

Summary: Tapinarof cream 1% demonstrated long-term safety, efficacy, and durability in the treatment of plaque psoriasis, with a high rate of disease clearance and remittive effect.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis The DERMIS-1 and DERMIS-2 Randomized Clinical Trials

Mark G. Lebwohl et al.

Summary: Treatment with 0.3% roflumilast cream once daily for 8 weeks showed better clinical outcomes compared to vehicle cream in patients with chronic plaque psoriasis. Further research is required to compare efficacy with other active treatments and assess long-term efficacy and safety.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Dermatology

A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes

Linda Stein Gold et al.

Summary: The study shows that Tapinarof cream can significantly improve symptoms of psoriasis patients, especially with the use of 1% once daily, exhibiting apparent efficacy from week 2 and maintaining stability from week 8 to 16. Most adverse events were mild or moderate, and further confirmation in larger-scale studies is needed.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Joint AADeNPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Craig A. Elmets et al.

Summary: This guideline addresses important clinical questions in psoriasis management and care, providing treatment recommendations and emphasizing the role of dermatologists in monitoring and educating patients, focusing on benefits and risks.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

Mark G. Lebwohl et al.

Summary: Tapinarof cream used once daily was more effective in reducing the severity of plaque psoriasis over 12 weeks compared to vehicle control, but was associated with local adverse events and headache. Larger and longer trials are needed to evaluate the efficacy and safety of tapinarof cream.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Dermatology

Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent

Robert Bissonnette et al.

Summary: Tapinarof is a novel topical therapeutic agent for psoriasis and atopic dermatitis, which works by specifically binding and activating the AhR to downregulate proinflammatory cytokines and regulate skin barrier proteins. Its efficacy and tolerability in early clinical trials are attributed to AhR signaling-mediated effects on immune and skin cells.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Psoriasis Prevalence in Adults in the United States

April W. Armstrong et al.

Summary: The prevalence of psoriasis among US adults was 3.0%, with no significant differences in prevalence by gender, race/ethnicity, marital status, education, income, or medical insurance status. The prevalence has remained stable since 2003.

JAMA DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology